MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast
MIRA Pharmaceuticals, Inc. (MIRA)
Company Research
Source: Accesswire
PHOENIX, AZ / ACCESSWIRE / August 9, 2023 / The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) ("the Company"), a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog. CEO of the Company, Erez Aminov, joined Stock Day host Kevin Davis following the company's NASDAQ IPO.The company's lead drug candidate, MIRA1a, is being developed to treat anxiety and cognitive decline in the elderly and chronic pain without impurities and the negative side effects associated with cannabis plant extracts, Aminov said. "MIRA1a is a major pipeline drug, a groundbreaking new molecular entity patented worldwide," he shared, noting it was designed to be the first unscheduled THC analog to address anxiety, chronic pain, and cognitive impairment without THC impurities and side effects."We have shown that we don't only treat anxiety, chronic pain, and cognitive impairment through preclinical trials, but we've also shown that we enhance cognition…in a
Show less
Read more
Impact Snapshot
Event Time:
MIRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRA alerts
High impacting MIRA Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MIRA
News
- MIRA Pharmaceuticals (NASDAQ:MIRA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- MIRA Pharmaceuticals (NASDAQ:MIRA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- MIRA Pharmaceuticals (NASDAQ:MIRA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MIRA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- MIRA Pharmaceuticals (NASDAQ:MIRA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MIRA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- MIRA Pharmaceuticals (NASDAQ:MIRA) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MIRA
Sec Filings
- 12/22/25 - Form 8-K
- 12/5/25 - Form 8-K
- 12/5/25 - Form 424B5
- MIRA's page on the SEC website